Logo

AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III FLAURA Study for 1L EGFR-Mutated Non-Small Cell Lung Cancer

Share this

AstraZeneca Reports Updated Positive Results of Tagrisso (osimertinib) in P-III FLAURA Study for 1L EGFR-Mutated Non-Small Cell Lung Cancer

Shots:

  • The P-III FLAURA study involves assessing of Tagrisso (80mg- qd) vs EGFR-TKIs (erlotinib- 50mg- qd /gefitinib- 250mg- qd) in 556 patients with LA/metastatic EGFRm NSCLC across 29 countries
  •  In Jul’2017- the P-III FLAURA study met its 1EPs of improvement in PFS and the updated results demonstrated improvement in OS with safety & tolerability profile consistent with the previous studies
  • Tagrisso is an irreversible EGFR-TKI targeting both EGFR-sensitizing and EGFR T790M-resistance mutations with clinical activity against CNS metastases and is an approved therapy in 70+ countries for 1L EGFRm advanced NSCLC and in 80+ countries for EGFR T790M mutation-positive advanced NSCLC

Click here to­ read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions